Y-mAbs Therapeutics Statistics
Total Valuation
YMAB has a market cap or net worth of $386.68 million. The enterprise value is $327.51 million.
Important Dates
The last earnings date was Friday, August 8, 2025, before market open.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
YMAB has 45.44 million shares outstanding. The number of shares has increased by 2.79% in one year.
| Current Share Class | 45.44M |
| Shares Outstanding | 45.44M |
| Shares Change (YoY) | +2.79% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 1.72% |
| Owned by Institutions (%) | 41.48% |
| Float | 21.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.48 |
| Forward PS | 4.58 |
| PB Ratio | 4.42 |
| P/TBV Ratio | 4.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.00, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.00 |
| Quick Ratio | 3.40 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -24.31% and return on invested capital (ROIC) is -12.09%.
| Return on Equity (ROE) | -24.31% |
| Return on Assets (ROA) | -8.67% |
| Return on Invested Capital (ROIC) | -12.09% |
| Return on Capital Employed (ROCE) | -19.21% |
| Revenue Per Employee | $821,010 |
| Profits Per Employee | -$213,692 |
| Employee Count | 104 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.73 |
Taxes
| Income Tax | -394,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.47% in the last 52 weeks. The beta is 0.56, so YMAB's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -14.47% |
| 50-Day Moving Average | 5.18 |
| 200-Day Moving Average | 6.66 |
| Relative Strength Index (RSI) | 81.49 |
| Average Volume (20 Days) | 1,620,232 |
Short Selling Information
The latest short interest is 2.23 million, so 4.91% of the outstanding shares have been sold short.
| Short Interest | 2.23M |
| Short Previous Month | 2.49M |
| Short % of Shares Out | 4.91% |
| Short % of Float | 10.59% |
| Short Ratio (days to cover) | 13.98 |
Income Statement
In the last 12 months, YMAB had revenue of $85.39 million and -$22.22 million in losses. Loss per share was -$0.49.
| Revenue | 85.39M |
| Gross Profit | 69.58M |
| Operating Income | -18.11M |
| Pretax Income | -23.97M |
| Net Income | -22.22M |
| EBITDA | -17.77M |
| EBIT | -18.11M |
| Loss Per Share | -$0.49 |
Full Income StatementBalance Sheet
The company has $62.29 million in cash and $3.12 million in debt, giving a net cash position of $59.17 million or $1.30 per share.
| Cash & Cash Equivalents | 62.29M |
| Total Debt | 3.12M |
| Net Cash | 59.17M |
| Net Cash Per Share | $1.30 |
| Equity (Book Value) | 87.49M |
| Book Value Per Share | 1.93 |
| Working Capital | 68.84M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.80 million and capital expenditures -$127,000, giving a free cash flow of -$17.92 million.
| Operating Cash Flow | -17.80M |
| Capital Expenditures | -127,000 |
| Free Cash Flow | -17.92M |
| FCF Per Share | -$0.39 |
Full Cash Flow StatementMargins
Gross margin is 81.49%, with operating and profit margins of -21.21% and -26.03%.
| Gross Margin | 81.49% |
| Operating Margin | -21.21% |
| Pretax Margin | -26.49% |
| Profit Margin | -26.03% |
| EBITDA Margin | -20.81% |
| EBIT Margin | -21.21% |
| FCF Margin | n/a |
Dividends & Yields
YMAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.79% |
| Shareholder Yield | -2.79% |
| Earnings Yield | -5.75% |
| FCF Yield | -4.63% |
Analyst Forecast
The average price target for YMAB is $15.02, which is 76.50% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.02 |
| Price Target Difference | 76.50% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 18.56% |
| EPS Growth Forecast (5Y) | -5.69% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
YMAB has an Altman Z-Score of 3 and a Piotroski F-Score of 3.
| Altman Z-Score | 3 |
| Piotroski F-Score | 3 |